Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and Roche today released preliminary results for a clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.

Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that MMF was superior to IVC in inducing treatment response in this disease. The results relate to the induction phase of this study, which was designed to measure treatment response in patients after 24 weeks of induction therapy with 185 patients in the MMF arm and 185 in the IVC arm. The results indicate similar treatment responses with 56.2% in the MMF arm and 53% in the IVC arm were observed. Additional analyses are ongoing to determine the potential for a regulatory submission and Aspreva plans to present the final results at an appropriate scientific forum.

Based on preliminary analysis, it appears that, in general, the adverse events experienced by patients in both arms of the study are consistent with those observed in lupus nephritis patients receiving immunosuppressive therapy. Overall incidence of adverse events was comparable in both treatment arms. Aspreva will host a conference call today at 9:30 a.m. ET (6:30 a.m. PT) to discuss these preliminary results.

About Lupus Nephritis

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered life-threatening, but rare, is the most serious manifestation of SLE. If left untreated, it can lead to kidney failure, need of dialysis, and potentially death. It is a complicated disease as patients typic
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... In strong collaboration with clinical research partners, Hocoma recently ... LokomatPro that offers greater system capabilities. Since the launch ... LokomatPro has established itself as an effective intervention for ... and injuries resulting in gait impairment. ...
... of a clinical research study at Sharp Memorial Hospital indicate ... functional recovery, survival and quality of life at ... for heart failure.  The study was released in the June ... of Cardiology. (Photo: http://photos.prnewswire.com/prnh/20110628/LA27443 ) ...
Cached Medicine Technology:Hocoma Launches New Version of its Established Gait Training Device LokomatPro 2New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients 2New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients 3
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... continues between Israelis and Palestinians, a new University of ... inflicting on the region,s children. Palestinian and Israeli ... violence, they are also being psychologically scarred by the ... study, presented earlier this summer at the International Society ...
... intestine provide the environmental trigger that initiates and perpetuates ... to inflammatory bowel disease (IBD), a study led by ... Inflammatory bowel disease results from a loss of ... microbes that inhabit the intestine. "In this study, we ...
... as a sort of fertilizer that feeds breast ... in animal models, researchers at UCLA,s Jonsson Comprehensive ... is biologically reprogramming the immune cells that are ... from soldiers protecting the body against disease into ...
... Journal of Sexual Medicine reveals that women with low ... placebo. , Andrea Bradford, Ph.D., a psychologist at Baylor College ... University of Texas at Austin, analyzed the behaviors and symptoms ... in a large clinical trial of a drug treatment for ...
... , WEDNESDAY, Sept. 15 (HealthDay News) -- In ongoing early ... toward reducing the tell-tale inflammatory impact of the deadly bone ... drug -- called INCB018424 -- shows promise are reported in ... of Medicine . "The problem with myelofibrosis is the ...
... 14, 2010) A new investigational drug designed to penetrate ... patient for the first time ever at the Virginia G. ... a potent, targeted compound designed to selectively kill cancer cells, ... Phase I clinical trial. Pancreatic cancer is a fast-growing and ...
Cached Medicine News:Health News:Study: How Palestinian and Israeli children are psychologically scarred by exposure to war 2Health News:Study: How Palestinian and Israeli children are psychologically scarred by exposure to war 3Health News:Bacteria identified that may lead to inflammatory bowel disease in certain individuals 2Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:Experimental Drug Shows Promise for Bone Marrow Disorder 2Health News:Experimental Drug Shows Promise for Bone Marrow Disorder 3Health News:New investigational compound targets pancreatic cancer cells 2
... easy to operate and maintain. The units ... flexible snap-seal pockets which minimize the potential ... the water. Offered in two-, four-, and ... bags of various sizes. ThermoLine Thawing Systems ...
Conventional Digitally-Controlled Water Baths...
Dry thaws. Has an ingenious (pat. pending) massaging sytem that utilizes the tempered bladders as hands. There are no unreliable mechanical parts involved. Two pumps pressurize different segments of ...
... of two principal components. The AB5000 Console is ... pumps and can be used either in the ... The AB5000 Ventricle is a disposable blood pump ... ventricles of the heart and is designed to ...
Medicine Products: